Sign in
Taking peoplePhase 2

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Key facts

Who runs it
Chinese PLA General Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
9 people, planned
Started
5 Sept 2025
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Anti-BCMA-CD19 CAR-T cells
Record updated
3 September 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (24)Hide the full registry criteria

Who can take part

  • To participate, subjects must meet all of the following criteria:
  • Aged 18 to 75 years, inclusive, regardless of sex
  • Meet the 2019 ACR/EULAR classification criteria for IgG4-related disease
  • Involvement of two or more important systems/sites (including but not limited to the pancreas, bile ducts, kidneys and dura mater)
  • Relapsed or refractory IgG4-RD: The disease either remains active after 3 months of glucocorticoid and/or rituximab therapy or relapses within 6 months post-treatment
  • Important organ function meeting the following conditions:; Bone marrow: (i) neutrophil count ≥1×10\^9/L (excluding disease-related neutropenia); (ii) hemoglobin ≥60 g/L; Hepatic function: ALT≤3×ULN (elevation caused by disease may be excluded); AST≤3×ULN (elevation caused by disease may be excluded); TBIL≤1.5×ULN (elevation caused by disease may be excluded); Renal function: creatinine clearance (Cockcroft-Gault formula) ≥30 ml/min (excluding acute decline due to disease); Coagulation: international normalized ratio (INR) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN; Cardiac function: stable hemodynamics
  • Women of childbearing potential and male subjects with partners of childbearing potential must use medically accepted contraception or abstain during study treatment and for at least 12 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must not be breastfeeding
  • Voluntary participation in this clinical study with signed informed consent and willingness to comply with study procedures and follow-up
  • Patent superficial peripheral veins adequate for intravenous infusion

Who cannot take part

  • Participation in other clinical trials within three months before enrollment
  • Receipt of any investigational drug within 12 weeks before screening or within five half-lives of the agent (whichever is longer)
  • History of severe drug allergy or allergic constitution
  • Current or suspected uncontrollable or treatment-requiring fungal, bacterial, viral or other infections
  • Central nervous system disease (excluding disease-related epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis or central nervous system vasculitis)
  • Cardiac insufficiency that precludes participation
  • Congenital malformation or nutritional disorder causing severe organ impairment
  • History of malignancy within the past five years
  • End-stage renal failure
  • Positive hepatitis B surface antigen and hepatitis B core antibody with HBV-DNA titers above the assay limit of detection; positive hepatitis C antibody with HCV-RNA positivity; positive human immunodeficiency virus antibody; positive syphilis serology
  • Psychiatric disorders or severe cognitive impairment
  • Subjects will be excluded if any of the following criteria are met:
  • Congenital immunoglobulin deficiency
  • Pregnant or intending to become pregnant
  • Any other reason deemed by the investigator to preclude enrollment

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • IgG4 related disease or B-cell mediated autoimmune disorders

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not improved after standard treatments such as glucocorticoids or rituximab.

Read full original descriptionShow less

The main questions this study aims to answer are:

* What medical problems (side effects) occur after receiving anti-BCMA-CD19 CAR-T cell therapy? * Does anti-BCMA-CD19 CAR-T cell therapy improve IgG4-RD disease activity scores at 12 weeks and 26 weeks?

Participants will:

* Have their own blood immune cells collected by a procedure called leukapheresis * Receive short-term chemotherapy to prepare the immune system * Receive one intravenous infusion of anti-BCMA-CD19 CAR-T cells * Return for regular clinic visits over 26 weeks for safety checks, blood tests, and imaging * May be followed for up to one year in total

The group in the trial

  • Anti-BCMA-CD19 CAR-T cellsTreatment being tested

    Participants will undergo leukapheresis for autologous T-cell collection, followed by ex vivo transduction with a lentiviral vector encoding a dual-target CAR against BCMA and CD19. After lymphodepletion chemotherapy with fludarabine (30 mg/m²/day) and cyclophosphamide (250 mg/m²/day) for 3 consecutive days, participants will receive a single intravenous infusion of the manufactured CAR-T cells at the assigned dose level. Post-infusion, participants will be monitored for safety, tolerability, and preliminary efficacy through Week 52.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploratory Clinical Study of Anti-BCMA-CD19 CAR-T Cell Therapy for Relapsed/Refractory IgG4-Related Disease
Criteria questions
Built from NCT07148791, who can take part
Record updated
3 September 2025